Anticonvulsants |
Statewide PDL Prior Authorization Criteria |
Anticoagulants |
Statewide PDL Prior Authorization Criteria Policy |
Growth Hormones |
Statewide PDL Prior Authorization Criteria policy |
Glucocorticoids, Oral |
Statewide PDL Prior Authorization Criteria policy |
Glucocorticoids, Inhaled |
Statewide PDL Prior Authorization Criteria policy |
GI Motility, Chronic |
Statewide PDL Prior Authorization Criteria policy |
Fluoroquinolones, Oral |
Statewide PDL Prior Authorization Criteria policy |
Zeposia |
Statewide PDL Prior Authorization Criteria Policy |
VMAT2 Inhibitors |
Statewide PDL Prior Authorization Criteria Policy |
Vitamin D Analogs |
Statewide PDL Prior Authorization Criteria Policy |
Vaginal Anti-Infectives |
Statewide PDL Prior Authorization Criteria Policy |
Urinary Anti-Infectives |
Statewide PDL Prior Authorization Criteria Policy |
Urea Cycle Disorder Agents |
Statewide PDL Prior Authorization Criteria Policy |
Ulcerative Colitis Agents |
Statewide PDL Prior Authorization Criteria Policy |
Estrogens |
Statewide PDL Prior Authorization Criteria policy |
Erythropoiesis Stimulating Proteins |
Statewide PDL Prior Authorization Criteria policy |
Epinephrine, Self-Injected |
Statewide PDL Prior Authorization Criteria policy |
Enzyme Replacements, Gaucher Disease |
Statewide PDL Prior Authorization Criteria policy |
Dupixent |
Statewide PDL Prior Authorization Criteria policy |
Cytokine and CAM Antagonists |
Statewide PDL Prior Authorization Criteria policy |
COPD Agents |
Statewide PDL Prior Authorization Criteria policy |
Contraceptives, Oral |
Statewide PDL Prior Authorization Criteria policy |
Contraceptives, Other |
Statewide PDL Prior Authorization Criteria policy |
Colony Stimulating Factors |
Statewide PDL Prior Authorization Criteria policy |
Cephalosporins |
Statewide PDL Prior Authorization Criteria policy |
Beta Blockers |
Statewide PDL Prior Authorization Criteria policy |
Calcium Channel Blockers |
Statewide PDL Prior Authorization Criteria policy |
Bronchodilators, Beta Agonists |
Statewide PDL Prior Authorization Criteria policy |
BPH Treatments |
Statewide PDL Prior Authorization Criteria policy |
Botulinum Toxins |
Statewide PDL Prior Authorization Criteria policy |
Bone Density Regulators |
Statewide PDL Prior Authorization Criteria policy |
Blood Glucose Meters and Test Strips |
Statewide PDL Prior Authorization Criteria |
Bladder Relaxant Preparations |
Statewide PDL Prior Authorization Criteria |
Bile Salts |
Statewide PDL Prior Authorization Criteria |
Tysabri |
Statewide PDL Prior Authorization Criteria Policy |
Thyroid Hormones |
Statewide PDL Prior Authorization Criteria Policy |
Thrombopoietics |
Statewide PDL Prior Authorization Criteria Policy |
Thalidomide and Derivatives |
Statewide PDL Prior Authorization Criteria Policy |
Tetracyclines |
Statewide PDL Prior Authorization Criteria Policy |
Stimulants and Related Agents |
Statewide PDL Prior Authorization Criteria Policy |
Steroids, Topical |
Statewide PDL Prior Authorization Criteria Policy |
Smoking Cessation |
Statewide PDL Prior Authorization Criteria Policy |
Skeletal Muscle Relaxants |
Statewide PDL Prior Authorization Criteria Policy |
Sickle Cell Anemia Agents |
Statewide PDL Prior Authorization Criteria Policy |
Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled |
Statewide PDL Prior Authorization Criteria Policy |
Proton Pump Inhibitors |
Statewide PDL Prior Authorization Criteria policy |
Progestational Agents |
Statewide PDL Prior Authorization Criteria Policy |
Prenatal Vitamins |
Statewide PDL Prior Authorization Criteria Policy |
Potassium Removing Agents |
Statewide PDL Prior Authorization Criteria Policy |
Platelet Aggregation Inhibitors |
Statewide PDL Prior Authorization Criteria Policy |
Pitutiary Suppressive Agents, LHRH |
Statewide PDL Prior Authorization Criteria Policy |
Anxiolytics |
Statewide PDL Prior Authorization Criteria policy |
Antivirals, Influenza |
Statewide PDL Prior Authorization Criteria policy |
Phosphate Binders |
Statewide PDL Prior Authorization Criteria Policy |
Antivirals, Herpes |
Statewide PDL Prior Authorization Criteria policy |
Penicillins |
Statewide PDL Prior Authorization Criteria Policy |
Antivirals, CMV |
Statewide PDL Prior Authorization Criteria policy |
Pancreatic Enzymes |
Statewide PDL Prior Authorization Criteria Policy |
Antipsychotics |
Statewide PDL Prior Authorization Criteria policy |
Zulresso |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Xyrem & Xywav |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antipsoriatics, Topical |
Statewide PDL Prior Authorization Criteria policy |
Antipsoriatics, Oral |
Statewide PDL Prior Authorization Criteria policy |
Xiaflex |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Vyndaqel & Vyndamax |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antiparkinson's Agents |
Statewide PDL Prior Authorization Criteria policy |
Tepezza |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antiparasitics, Topical |
Statewide PDL Prior Authorization Criteria policy |
Synagis |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Sucraid |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antimalarials |
Statewide PDL Prior Authorization Criteria policy |
Sublingual Immunotherapy Medications |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Strensiq |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Somatuline Depot |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Spinal Muscular Atrophy Medications |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Sandostatin LAR Depot |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Rituxan & Rituximab Biosimilars |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Radicava |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Quantity Limits |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Qbrexza |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Pulmozyme |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Phenylketonuria Medications |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Palforzia |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Pulmonary Arterial Hypertension (PAH) Agents, Injectable |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Onpattro,Tegsedi and Amvuttra |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Oncology Agents, Oral |
Statewide PDL Prior Authorization Criteria Policy |
Oncology, IV/Injectable |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Oncology Agents, Breast Cancer |
Statewide PDL Prior Authorization Criteria Policy |
Nuedexta |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Non-Formulary Medical Necessity |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Myalept |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Isturisa |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Immune Globulin Products |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Corticotropin (H.P. Acthar, Purified Cortrophin Gel) |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Givlaari |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Gattex |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Gamifant |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Continuous Glucose Monitor Systems |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Firdapse |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Fabry Disease Medications |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Enspryng |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antihyperuricemics |
Statewide PDL Prior Authorization Criteria policy |
Antihypertensives, Sympatholytic |
Statewide PDL Prior Authorization Criteria policy |
Duchenne Muscular Dystrophy (DMD) Antisense Oligonucleotides |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antihistamines, Minimally Sedating |
Statewide PDL Prior Authorization Criteria policy |
Antihemophilia Agents |
Statewide PDL Prior Authorization Criteria policy |
Daraprim |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antifungals, Topical |
Statewide PDL Prior Authorization Criteria policy |
Crysvita |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antifungals, Oral |
Statewide PDL Prior Authorization Criteria policy |
Antiemetic-Antivertigo Agents |
Statewide PDL Prior Authorization Criteria policy |
Cough and Cold Medications for Children less than 4 |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antidepressants, SSRI |
Statewide PDL Prior Authorization Criteria policy |
Compounds |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antidepressants, Other |
Statewide PDL Prior Authorization Criteria policy |
Chimeric Antigen Receptor T-cell (CAR-T) Immunotherapy |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antibiotics, GI and related |
Statewide PDL Prior Authorization Criteria policy |
C5b Complement Inhibitors |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Brineura |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Cystic Fibrosis Biologic Response Modifiers |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antibiotics, Topical |
Statewide PDL Prior Authorization Criteria policy |
Alpha-1 Proteinase Inhibitors |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Antibiotics, Inhaled |
Statewide PDL Prior Authorization Criteria policy |
Otic Antibiotics |
Statewide PDL Prior Authorization Criteria Policy |
Opioid Overdose Agents |
Statewide PDL Prior Authorization Criteria Policy |
Opioid Dependence Treatments |
Statewide PDL Prior Authorization Criteria Policy |
Ophthalmics, Glaucoma |
Statewide PDL Prior Authorization Criteria Policy |
Antianginal Agent |
Statewide PDL Prior Authorization Criteria policy |
Ophthalmics, Antibiotic-Steroid Combinations |
Statewide PDL Prior Authorization Criteria Policy |
Angiotensin Modulators |
Statewide PDL Prior Authorization Criteria policy |
Ophthalmics, Antibiotics |
Statewide PDL Prior Authorization Criteria Policy |
Angiotensin Modulator Combinations |
Statewide PDL Prior Authorization Criteria policy |
Androgenic Agents |
Statewide PDL Prior Authorization Criteria policy |
Ophthalmics, Anti-inflammatories |
Statewide PDL Prior Authorization Criteria Policy |
Analgesics, Opioid Short-Acting |
Statewide PDL Prior Authorization Criteria policy |
Ophthalmics, Allergic Conjunctivitis |
Statewide PDL Prior Authorization Criteria Policy |
Analgesics, Opioid Long-Acting |
Statewide PDL Prior Authorization Criteria policy |
Analgesics, Non-Opioid Barbituate Combinations |
Statewide PDL Prior Authorization Criteria Policy |
NSAIDS |
Statewide PDL Prior Authorization Criteria Policy |
Neuropathic Pain Agents |
Statewide PDL Prior Authorization Criteria Policy |
Alzheimer's Agents |
Statewide PDL Prior Authorization Criteria policy |
Multiple Sclerosis Agents |
Statewide PDL Prior Authorization Criteria Policy |
Migraine Prevention Agents |
Statewide PDL Prior Authorization Criteria Policy |
Migraine Acute Treatment Agents |
Statewide PDL Prior Authorization Criteria Policy |
Methotrexate |
Statewide PDL Prior Authorization Criteria Policy |
Macular Degeneration Agents |
Statewide PDL Prior Authorization Criteria Policy |
Macrolides |
Statewide PDL Prior Authorization Criteria Policy |
Monoclonal Antibodies (MABs)- Anti-IL, Anti-IgE, Anti-TSLP |
Statewide PDL Prior Authorization Criteria Policy |
Local Anesthetics, Topical |
Statewide PDL Prior Authorization Criteria Policy |
Lipotropics, Statins |
Statewide PDL Prior Authorization Criteria Policy |
Lipotropics, Other |
Statewide PDL Prior Authorization Criteria Policy |
Leukotriene Modifiers |
Statewide PDL Prior Authorization Criteria Policy |
Iron, Parenteral |
Statewide PDL Prior Authorization Criteria Policy |
Iron Chelating Agents |
Statewide PDL Prior Authorization Criteria Policy |
Intranasal Rhinitis Agents |
Statewide PDL Prior Authorization Criteria Policy |
Intra-Articular Hyaluronates |
Statewide PDL Prior Authorization Criteria Policy |
Acne Agents, Topical |
Statewide PDL Prior Authorization Criteria Policy |
Acne Agents, Oral |
Statewide PDL Prior Authorization Criteria Policy |
Immunosuppressives, Oral |
Statewide PDL Prior Authorization Criteria Policy |
Immunomodulators, Topical |
Statewide PDL Prior Authorization Criteria Policy |
Immunomodulators, Atopic Dermatitis |
Statewide PDL Prior Authorization Criteria Policy |
Hypoglycemics, TZDs |
Statewide PDL Prior Authorization Criteria Policy |
Hypoglycemics, Sulfonylureas |
Statewide PDL Prior Authorization Criteria Policy |
Hypoglycemics, SGLT2 Inhibitors |
Statewide PDL Prior Authorization Criteria Policy |
Hypoglycemics, Metformins |
Statewide PDL Prior Authorization Criteria Policy |
Hypoglycemics, Meglitinides |
Statewide PDL Prior Authorization Criteria Policy |
Hypoglycemics, Insulin and Related Agent |
Statewide PDL Prior Authorization Criteria Policy |
Hypoglycemics, Incretin Mimetics/Enhancers |
Statewide PDL Prior Authorization Criteria Policy |
Hypoglycemics, Alpha-Glucosidase Inhibitors |
Statewide PDL Prior Authorization Criteria Policy |
Hypoglycemia Treatments |
Statewide PDL Prior Authorization Criteria Policy |
HIV/AIDS Antiretrovirals |
Statewide PDL Prior Authorization Criteria Policy |
Histamine 2 Receptor Blockers |
Statewide PDL Prior Authorization Criteria Policy |
Hereditary Angioedema Agents |
Statewide PDL Prior Authorization Criteria Policy |
Hepatitis C Agents |
Statewide PDL Prior Authorization Criteria Policy |
Hepatitis B Agents |
Statewide PDL Prior Authorization Criteria Policy |
Hematopoietic Mixtures |
Statewide PDL Prior Authorization Criteria Policy |
H. Pylori Treatments |
Statewide PDL Prior Authorization Criteria Policy |
Sedative Hypnotics |
Statewide PDL Prior Authorization Criteria |
Systemic Lupus Erythematosus (SLE) Agents |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Enzyme Replacement Therapy, Pompe Disease |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Luxturna |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Bylvay |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Vyvgart |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Livmarli |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Gene Therapy Agents |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Xenpozyme |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Skysona |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Alcohol Use Disorder Agents |
Statewide PDL Prior Authorization Criteria Policy |
Obesity Treatment Agents |
Statewide PDL Prior Authorization Criteria Policy |
Dry Eye Treatments |
Statewide PDL Prior Authorization Criteria Policy |
Antifibrotic Respiratory Agents |
Statewide PDL Prior Authorization Criteria Policy |
Tzield |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Relyvrio |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
Alzheimer's Antiamyloid Monoclonal Antibodies |
Highmark Wholecare Non-PDL Prior Authorization Criteria |